After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...

Peninsula biotech company Vivace Therapeutics has raised $35 million to push mesothelioma drug toward late-stage trial.

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

Swiss pharmaceutical company Novartis has renewed its 15,865-square-foot office at Property & Building Corporation’s 10 ...

UK-based Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today ...

Glenmark Pharma has appointed Starcom for the media mandate of one of its brands, sources have confirmed to e4m. Further ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

Q4 2024 Earnings Call Transcript March 11, 2025 Legend Biotech Corporation beats earnings expectations. Reported EPS is $0.08 ...

Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired ...

The "mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com ...